Evidence map›Paper›PMID 28877720›Full record

ArticleBMC cancer2017

Reduced ovarian reserve in young early breast cancer patients: preliminary data from a prospective cohort trial.

Antonia Wenners, Jana Grambach, Juliane Koss, Nicolai Maass, Walter Jonat, Andreas Schmutzler, Christoph Mundhenke

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 4 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 4 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Cytotoxic Activity of Antineoplastic Agents on Fertility: A Systematic Review.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2020
    Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Antonia WennersOB/GYN, University of Kiel, UKSH, Arnold-Heller-Straße 3, 24105, Kiel, Germany. antonia.wenners@gmx.de.
Jana GrambachOB/GYN, University of Kiel, UKSH, Arnold-Heller-Straße 3, 24105, Kiel, Germany.
Juliane KossOB/GYN, University of Kiel, UKSH, Arnold-Heller-Straße 3, 24105, Kiel, Germany.
Nicolai MaassOB/GYN, University of Kiel, UKSH, Arnold-Heller-Straße 3, 24105, Kiel, Germany.
Walter JonatOB/GYN, University of Kiel, UKSH, Arnold-Heller-Straße 3, 24105, Kiel, Germany.
Andreas SchmutzlerOB/GYN, Reproductive Medicine, University of Kiel, UKSH, Arnold-Heller-Straße 3, 24105, Kiel, Germany.
Christoph MundhenkeOB/GYN, University of Kiel, UKSH, Arnold-Heller-Straße 3, 24105, Kiel, Germany.
Kiel University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe numerous side effects of chemotherapy in patients with breast cancer are well known. However, the precise effects of chemotherapy on ovarian function in premenopausal women are poorly investigated. The patients are at risk of developing sexual hormone deficiency and impaired fertility. This prospective cohort study addresses predictive parameters of ovarian reserve after chemotherapy.

methodsFifty-one premenopausal women (28-46 years) with primary breast cancer were included in the trial. All of them received anthracycline-based chemotherapy (n = 18), or combinations with taxanes (n = 30), or anthracycline-free chemotherapy (n = 3). Changes in hormone levels (LH, FSH, E2 and Anti-Müllerian hormone (AMH)), antral follicle count (AFC), and amenorrhea were determined before (V1), and 6, 12 and 24 months after the initiation of chemotherapy (V2-V4). Quality of life parameters were evaluated. The additional impact of parity, BMI, and smoking on ovarian reserve was also assessed.

resultsAFC and AMH fell very markedly after chemotherapy and did not return to pre-treatment levels until V4. A significant positive correlation was noted in AFC before and 1 year after chemotherapy. AMH levels at V2-V4 were significantly correlated with those registered at V1. AFC and AMH were negatively correlated with age. Continued smoking had a significant detrimental effect on AFC after 24 months. LH and FSH levels increased between V1 and V2 and fell at V3 and V4, but stayed above pre-chemotherapy values. Two years after the start of chemotherapy 31/51 patients were amenorrhoic while 17 resumed their menstrual cycle; this was not influenced by the type of chemotherapy or age. Non-smokers were 13 times more likely to resume their menstruation than smokers. Quality of life (QL) was significantly lower 6 months after the initiation of chemotherapy. QL at one and 2 years after chemotherapy did not differ significantly from pre-chemotherapy scores.

conclusionsOur study contributes to a better understanding and prediction of ovarian reserve in young early breast cancer patients undergoing chemotherapy. The data suggest that personal counseling in regard of the preservation of fertility should be offered especially to patients of a higher age, with low AMH levels or low follicle counts. Patients should be advised to stop smoking in order to enhance the likelihood of preserving their fertility.

Indexed as

Ovarian ReserveAdultAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBiomarkersBreast NeoplasmsFemaleHumansMenstrual CycleMiddle AgedOvarian FollicleOvaryPremenopauseProspective StudiesQuality of LifeAntineoplastic AgentsBiomarkersAMHBreast cancerFertility preservationOvarian reserve

Identifiers

PMID28877720
PMCPMC5588613
OpenAlexW2751580658

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.